What does this research mean for the field?

Higher plasma levels of specific short-chain fatty acids, including valerate, isobutyrate, and hexanoate, as well as their combined exposure, are associated with a reduced risk of hypertensive disorders of pregnancy. Novelty: ClaimNovelty.INCREMENTAL. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

To investigate the individual and combined associations between mid-pregnancy plasma short-chain fatty acids (SCFAs) and the risk of developing hypertensive disorders of pregnancy (HDP).

August 29, 2026Maternal-Fetal MedicineOpen Access

Association between Plasma Short-Chain Fatty Acids and Hypertensive Disorders of Pregnancy: A Nested Case-Control Study

View Full Paper

Ask AI

Bookmark

Authors

DWDandan Wang LWLei Wu PFPei Feng

Discussion

Member takes

Overview

Nested case-control study reveals inverse associations between early-pregnancy plasma short-chain fatty acids and hypertensive disorders, indicating potential protective biomarker roles.

Key Points

To investigate the individual and combined associations between mid-pregnancy plasma short-chain fatty acids (SCFAs) and the risk of developing hypertensive disorders of pregnancy (HDP).
Conducted a nested case-control study matching 387 HDP cases (291 gestational hypertension, 96 preeclampsia or chronic hypertension with superimposed preeclampsia) with 387 non-HDP controls.
Quantified seven plasma SCFAs sampled at gestational weeks 16–20 prior to clinical disease onset.
Evaluated individual SCFA associations using multivariable logistic regression with false discovery rate (FDR) correction, and assessed joint effects via weighted quantile sum (WQS) regression.
Higher valerate levels were associated with reduced HDP risk per IQR increase (adjusted OR: 0.699, 95% CI: 0.516–0.946, FDR-corrected P=0.047), alongside lower median baseline levels in cases versus controls (9 [5–14] vs. 10 [6–18] ng/mL, P=0.001).
Isobutyrate (adjusted OR: 0.899, 95% CI: 0.826–0.980, FDR-corrected P=0.047) and hexanoate (adjusted OR: 0.686, 95% CI: 0.508–0.927, FDR-corrected P=0.047) were also significantly inversely associated with HDP risk.
Joint exposure to all seven SCFAs by WQS regression showed an inverse association with total HDP risk (adjusted OR: 0.230, 95% CI: 0.105–0.506) and gestational hypertension alone (adjusted OR: 0.740, 95% CI: 0.571–0.933).

Cite This Study

Wang et al. (2026) studied this question.

synapsesocial.com/papers/6a92994d8e5d7d1fc0c112f0 https://doi.org/10.1097/fm9.0000000000000375

View Full Paper

Ask AI

Bookmark

August 29, 2026Maternal-Fetal MedicineOpen Access

Association between Plasma Short-Chain Fatty Acids and Hypertensive Disorders of Pregnancy: A Nested Case-Control Study

View Full Paper

Ask AI

Bookmark

Authors

DWDandan Wang LWLei Wu PFPei Feng

Discussion

Member takes

Overview

Nested case-control study reveals inverse associations between early-pregnancy plasma short-chain fatty acids and hypertensive disorders, indicating potential protective biomarker roles.

Key Points

To investigate the individual and combined associations between mid-pregnancy plasma short-chain fatty acids (SCFAs) and the risk of developing hypertensive disorders of pregnancy (HDP).
Conducted a nested case-control study matching 387 HDP cases (291 gestational hypertension, 96 preeclampsia or chronic hypertension with superimposed preeclampsia) with 387 non-HDP controls.
Quantified seven plasma SCFAs sampled at gestational weeks 16–20 prior to clinical disease onset.
Evaluated individual SCFA associations using multivariable logistic regression with false discovery rate (FDR) correction, and assessed joint effects via weighted quantile sum (WQS) regression.
Higher valerate levels were associated with reduced HDP risk per IQR increase (adjusted OR: 0.699, 95% CI: 0.516–0.946, FDR-corrected P=0.047), alongside lower median baseline levels in cases versus controls (9 [5–14] vs. 10 [6–18] ng/mL, P=0.001).
Isobutyrate (adjusted OR: 0.899, 95% CI: 0.826–0.980, FDR-corrected P=0.047) and hexanoate (adjusted OR: 0.686, 95% CI: 0.508–0.927, FDR-corrected P=0.047) were also significantly inversely associated with HDP risk.
Joint exposure to all seven SCFAs by WQS regression showed an inverse association with total HDP risk (adjusted OR: 0.230, 95% CI: 0.105–0.506) and gestational hypertension alone (adjusted OR: 0.740, 95% CI: 0.571–0.933).

Cite This Study

Wang et al. (2026) studied this question.

synapsesocial.com/papers/6a92994d8e5d7d1fc0c112f0 https://doi.org/10.1097/fm9.0000000000000375

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark